Phathom Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated product revenue of $49.5 million for the third quarter, a substantial increase from $16.4 million in the same period last year. For the nine months ended September 30, 2025, total product revenue reached $117.5 million, compared to $25.6 million for the same period in 2024. This growth is attributed to the commercial launch of its products, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK, which began in late 2023.
Despite the increase in revenue, Phathom reported a net loss of $30.0 million for the third quarter, an improvement from a net loss of $85.6 million in the prior year. For the nine-month period, the net loss was $200.1 million, down from $259.9 million in 2024. The company’s operating expenses decreased to $58.6 million in the third quarter from $84.8 million a year earlier, primarily due to reduced selling, general, and administrative expenses, which fell by $24.5 million. Research and development expenses also saw a slight decline, totaling $7.0 million compared to $8.7 million in the previous year.
Operationally, Phathom has made strides in expanding its market presence. As of October 17, 2025, over 790,000 prescriptions for VOQUEZNA products have been filled, written by more than 34,100 prescribers. The company has achieved broad commercial coverage, with over 120 million U.S. commercial lives having access to its products. This expansion is part of Phathom's strategy to capitalize on the growing demand for its novel treatments for gastrointestinal diseases.
In terms of financial health, Phathom's cash and cash equivalents stood at $135.2 million as of September 30, 2025, a decrease from $297.3 million at the end of 2024. The company has incurred significant losses since its inception, with an accumulated deficit of $1.5 billion. Phathom has funded its operations primarily through equity offerings and debt financing, including a recent underwritten public offering that raised approximately $121.8 million. The company anticipates that its existing cash, along with projected product revenues, will be sufficient to fund operations for at least the next twelve months.
Looking ahead, Phathom plans to continue its focus on commercializing its products and exploring potential partnerships for further geographic expansion. The company is also evaluating additional clinical development opportunities for vonoprazan, including a Phase 2 clinical trial for eosinophilic esophagitis, which commenced in late 2025. Despite the positive trajectory in revenue, Phathom acknowledges the ongoing risks associated with achieving profitability and the potential need for additional funding to support its growth initiatives.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals develops and commercializes novel gastrointestinal treatments, primarily focusing on vonoprazan, a potent, fast-acting potassium-competitive acid blocker. Its core products target acid-related GI diseases such as GERD and H. pylori infection. The company emphasizes innovative therapies with improved efficacy over traditional PPIs, leveraging a differentiated mechanism of action, and aims to expand indications and formulations in the U.S. and international markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.